

The Journal of UROLOGY®

Editor

John T. Grayhack
1120 North Charles Street
Baltimore, Maryland 21201

Associate Editor

Terry D. Allen
Dallas, Texas

Associate Editor

Jay Y. Gillenwater
Charlottesville, Virginia

Section Editor

Stuart S. Howards
Charlottesville, Virginia

Section Editor

Patrick C. Walsh
Baltimore, Maryland

EDITORIAL BOARD

Mid-Atlantic

A. Barry Belman
Washington, D. C.

New England

Bernard Lytton
New Haven, Connecticut

New York

Michael J. Droller
New York, New York

North Central

Joseph W. Segura
Rochester, Minnesota

Northeastern

Abraham T. K. Cockett
Rochester, New York

South Central

Robert E. Donohue
Denver, Colorado

Southeastern

Floyd A. Fried
Chapel Hill, North Carolina

Western

Duncan E. Govan
Stanford, California

BOARD OF CONSULTANTS

Jonathan Epstein
Baltimore, Maryland

Howard M. Pollack
Cheltenham, Pennsylvania

Allyn W. Kimball
Baltimore, Maryland

William U. Shipley
Boston, Massachusetts

William M. Murphy
Memphis, Tennessee

Ronald R. Townsend
Denver, Colorado

Ryoichi Oyasu
Chicago, Illinois

Colin White
New Haven, Connecticut

Charles Y. C. Pak
Dallas, Texas

Alan Yagoda
New York, New York

FORMER EDITORS

Hugh H. Young
1917-1945

J. A. Campbell Colston
1945-1966

Hugh J. Jewett
1966-1977

William W. Scott
1977-1983

Herbert Brendler
1983-1985

The Journal of Urology (ISSN 0022-5347) is the Official Journal of the American Urological Association, Inc., and is published monthly by Williams & Wilkins, 428 East Preston Street, Baltimore, MD 21202. Second class postage paid at Baltimore, MD, and at additional mailing offices. Subscription rates individual \$193.00 (\$258.00 foreign); institutions \$215.00 (\$280.00 foreign); in-training \$95.00 (\$160.00 foreign); single copy \$23.00 (\$28.00 foreign).

Subscription prices subject to change. The GST number for Canadian subscribers is 123394371. To order call 1-800-638-6423 from anywhere in the U.S.; in Maryland call 1-800-638-4007. POSTMASTER: Send address changes to The Journal of Urology, 428 East Preston Street, Baltimore, MD 21202. Indexed by *Current Contents*, *Index Medicus*, and *Excerpta Medica*. Copyright © 1992 by American Urological Association, Inc.

The Journal of UROLOGY®

Volume 148

November 1992

Number 5

CLINICAL UROLOGY

Review Article

- Use of Alloplastic Biomaterials in Bladder Substitution. *M. J. Gleeson and D. P. Griffith* 1377

Original Articles

- Renal Colic in Pregnancy. *L. Stothers and L. M. Lee* 1383
- Therapeutic Use of Ganciclovir for Invasive Cytomegalovirus Infection in Cadaveric Renal Allograft Recipients. *M. L. Jordan, R. L. Hrebinko, Jr., J. S. Dummer, D. P. Hickey, R. Shapiro, C. A. Vivas, R. L. Simmons, T. E. Starzl and T. R. Hakala* 1388
- Intraoperative Sonography of Renal Tumors. *F. F. Marshall, S. S. Holdford and U. M. Hamper* 1393
- Clean Intermittent Catheterization and Urinary Diversion in Management of Renal Transplant Recipients With Lower Urinary Tract Dysfunction. *I. S. Gill, J. M. Hayes, E. E. Hodge and A. C. Novick* 1397
- Complications of Radical Cystectomy and Urinary Diversion: Retrospective Review of 675 Cases in 2 Decades. *H. A. Frazier, J. E. Robertson and D. F. Paulson* 1401
- Tamm-Horsfall Protein as Marker in Interstitial Cystitis. *A. R. Stone, P. Vogelsang, C. H. Miller and J. P. MacDermott* 1406
- Idiopathic Reduced Bladder Storage Versus Interstitial Cystitis. *S. A. Awad, S. MacDiarmid, J. B. Gajewski and R. Gupta* 1409
- Treated History of Noninvasive Grade 1 Transitional Cell Carcinoma. *G. R. Prout, Jr., B. A. Barton, P. P. Griffin and G. H. Friedell for National Bladder Cancer Group* (Editorial Comment by E. M. Messing) ... 1413
- Prognostic Significance of Mucosal Aneuploidy in Stage Ta/T1, Grade 3 Carcinoma of Bladder. *U. Norming, B. Tribukait, C. R. Nyman, B. Nilsson and N. Wang* (Editorial Comments by E. M. Messing, R. W. deVere White and M. J. Droller) 1420
- Value of Immediate or Early Catheterization of Traumatized Posterior Urethra. *S. Herschorn, A. Thijssen and S. B. Radomski* 1428
- Penile Extensibility: To What is it Related? *P. Moreira de Goes, E. Wespes and C. Schulman* 1432
- Vascular Impotence: Focal or Diffuse Penile Disease. *E. Wespes, P. Moreira de Goes and C. Schulman* 1435
- Preliminary Results With Nitric Oxide Donor Linsidomine Chlorhydrate in Treatment of Human Erectile Dysfunction. *C. G. Stief, F. Holmquist, M. Djamilian, H. Krah, K.-E. Andersson and U. Jonas* 1437
- Volume-Dependent Intracavernous Hemodilution During Pharmacologically Induced Penile Erections. *Q. H. Siraj, A. J. W. Hilson, J. Bomanji and M. Ahmed* 1441
- Early Experience With Controlled Girth and Length Expanding Cylinder of American Medical Systems Ultrex Penile Prosthesis. *D. K. Montague and M. M. Lakin* 1444
- Varicocele Treatment: Prospective Randomized Trial of 3 Methods. *J. Sayfan, Y. Soffer and R. Orda* 1447
- Test for Identification of Relevant Sympathetic Nerve Fibers During Nerve Sparing Retroperitoneal Lymphadenectomy. *K.-P. Dieckmann, H. Huland and A. J. Gross* (Editorial Comment by K. T. McVary) ... 1450
- Pilot Study to Evaluate Impact of Policy of Adjuvant Chemotherapy for High Risk Stage 1 Malignant Teratoma on Overall Relapse Rate of Stage 1 Cancer Patients. *R. T. D. Oliver, M. A. Raja, J. Ong and C. J. Gallagher* (Editorial Comments by J. P. Richie and J. P. Donohue) 1453
- Quantitative Measurement of Prostatic Blood Flow and Blood Volume by Positron Emission Tomography. *T. Inaba* 1457
- Characterization of Nonbacterial Prostatitis: Search for Etiology. *L. M. D. Shortliffe, R. G. Sellers and J. Schachter* 1461
- Randomized, Placebo-Controlled Multicenter Study of Efficacy and Safety of Terazosin in Treatment of Benign Prostatic Hyperplasia. *H. Lepor, S. Auerbach, A. Puras-Baez, P. Narayan, M. Soloway, F. Lowe, T. Moon, G. Leifer and P. Madsen* 1467
- Transurethral Surgery Using Intravesical Bupivacaine and Intravenous Sedation. *R. D. Matthews, J. F. Nolan, J. A. Libby-Straw and J. P. Sands, Jr.* 1475

Urological Neurology and Urodynamics

- Ambulatory Monitoring of Bladder Pressure in Low Compliance Neurogenic Bladder Dysfunction. *R. J. Webb, C. J. Griffiths, P. D. Ramsden and D. E. Neal* 1477

Pediatric Articles

- Quantitative Histological Analysis of Dilated Ureter of Childhood. *B. R. Lee, A. W. Partin, J. I. Epstein, D. M. Quinlan, J. A. Gosling and J. P. Gearhart* 1482
- Prenatal Diagnosis of Megacystis-Megaureter Association. *J. Mandell, R. L. Lebowitz, C. A. Peters, J. A. Estroff, A. B. Retik and B. R. Benacerraf* 1487

Contents continued on page A10

Endopyelotomy Associated Ureteral Necrosis: Complete Ureteral Replacement Using Boari Flap. R. S. Sutherland, R. R. Pfister and M. A. Koyle	1490
Influence of Preoperative Bladder Capacity and Compliance on Outcome of Artificial Sphincter Implantation in Patients With Neurogenic Sphincter Incompetence. F. I. P. de Badiola, D. Castro-Diaz, C. Hart-Austin and R. Gonzalez	1493
Adventitious Knots in Urethral Catheters: Report of 5 Cases. H. Foster, M. Ritchey and D. Bloom	1496
Radiographic and Serologic Correlates of Azotemia in Patients With Posterior Urethral Valves. P. A. Merguerian, G. A. McLorie, B. M. Churchill, P. H. McKenna and A. E. Khoury	1499
Urethral Stricture in Children: Treatment by Urethroplasty With Bladder Mucosa Graft. G. Monfort, D. Bretheau, V. Di Benedetto and R. Bankole	1504
Onlay Island Flap Urethroplasty: Variation on Theme. J. P. Gearhart and R. N. Borland	1507
Penoscrotal Transposition With Hypospadias: 1-Stage Repair. S. Perović and V. Vukadinović	1510
Intraoperative Spermatic Venography During Varicocele Surgery in Adolescents. R. R. Hart, H. G. Rushton and A. B. Belman	1514

Case Reports

Endocytosis of Calcium Oxalate Crystals and Proliferation of Renal Tubular Epithelial Cells in Patient With Type 1 Primary Hyperoxaluria. J. C. Lieske, B. H. Spargo and F. G. Toback	1517
Arteriovenous Fistula Complicating Endopyelotomy. E. S. Malden, D. Picus and R. V. Clayman	1520
Control of Massive Hematuria in Idiopathic Hemorrhagic Cystitis After Administration of Conjugated Estrogen. J. M. Rodriguez Luna, J. L. Teruel, J. Vallejo, F. J. Burgos, F. Lovaco and T. Mayayo	1524
Leiomyoma of Female Urethra: Case Report and Review. C. Cheng, F. M.-M. Lai and P. S. F. Chan	1526
Management of Injuries to Urethra, Bladder or Vagina Encountered During Difficult Placement of Artificial Urinary Sphincter in Female Patient. J. A. Salisz and A. C. Diokno	1528
Use of Polytetrafluoroethylene Tube Graft as Circumferential Neotunica During Placement of Penile Prosthesis. A. D. Seftel, R. D. Oates and I. Goldstein	1531
Epididymo-Orchitis Developing as Late Manifestation of Intravesical Bacillus Calmette-Guerin Therapy and Masquerading as Primary Testicular Malignancy: Report of 2 Cases. T. Truelson, K. I. Wishnow and D. E. Johnson	1534
Prostatic Abscess Due to Candida Tropicalis in Nonacquired Immunodeficiency Syndrome Patient. S. Yu and J. Provet	1536
Idiopathic Resistance to Luteinizing Hormone-Releasing Hormone Analogue in Patient With Prostatic Carcinoma. J. L. Jorion	1539
Recurrent Prostate Cancer Despite Undetectable Prostate Specific Antigen. T. K. Takayama, J. N. Krieger, L. D. True and P. H. Lange	1541
Papillary Adenocarcinoma in Seminal Vesicle Cyst Associated With Ipsilateral Renal Agenesis. Y. Okada, H. Tanaka, H. Takeuchi and O. Yoshida	1543

Special Communications

Hard Measures of Subjective Outcomes: Validating Symptom Indexes in Urology. M. P. O'Leary, M. J. Barry and F. J. Fowler, Jr.	1546
American Urological Association Symptom Index for Benign Prostatic Hyperplasia. M. J. Barry, F. J. Fowler, Jr., M. P. O'Leary, R. C. Bruskewitz, H. L. Holtgrewe, W. K. Mebust, A. T. K. Cockett and Measurement Committee of American Urological Association	1549
Correlation of American Urological Association Symptom Index With Self-Administered Versions of Madsen-Iversen, Boyarsky and Maine Medical Assessment Program Symptom Indexes. M. J. Barry, F. J. Fowler, Jr., M. P. O'Leary, R. C. Bruskewitz, H. L. Holtgrewe, W. K. Mebust and Measurement Committee of American Urological Association	1558
Editorial. J. T. Grayhack	1564

Letters to the Editor

Re: Balloon Ureteral Occlusion: New Reversible Technique in Management of Ureteral Fistulas, by D. R. Saltzstein, E. Orihuela and J. Reed. K. S. Fraser and M. Baga	1565
Re: Biopsy After External Beam Radiation Therapy for Adenocarcinoma of Prostate: Correlation With Original Histological Grade and Current Prostate Specific Antigen Levels, by T. C. Dugan, W. U. Shipley, R. H. Young, L. J. Verhey, A. F. Althausen, N. M. Heney, P. L. McManus and E. H. Abraham. J. N. Kabalin	1565

INVESTIGATIVE UROLOGY

Gonadotropin-Releasing Hormone Specific Binding Sites in Normal and Malignant Renal Tissue. N. Sion-Vardi, J. Kaneti, T. Segal-Abramson, J. Giat, J. Levy and Y. Sharoni	1568
Effect of PSK and Its Subfractions on Peripheral Blood Lymphocytes Mediated Cytotoxicity Against Urinary Bladder Tumor Cells. Y. Mizutani, Y. Nio and O. Yoshida	1571
Impaired Immune Response by Isoniazid Treatment During Intravesical BCG Administration in Guinea Pig. L. C. De Boer, P. A. Steerenberg, A. P. M. Van Der Meijden, B. Van Klingerren, W. H. De Jong, A. Elgersma, F. M. J. Debruyne and E. J. Ruitenberg	1577
Expression of Adhesion Molecules by Bladder Cancer Cells: Modulation by Interferon-Gamma and Tumor Necrosis Factor-Alpha. A. M. Jackson, A. B. Alexandrov, S. Prescott, K. James and G. D. Chisholm ..	1583

Diabetes Mellitus Impairs Neurogenic and Endothelium-Dependent Relaxation of Rabbit Corpus Cavernosum Smooth Muscle. <i>K. M. Azadzi and I. Saenz De Tejada</i>	1587
Microbial Adhesion and Biofilm Formation on Ureteral Stents In Vitro and In Vivo. <i>G. Reid, J. D. Denstedt, Y. S. Kang, D. Lam and C. Nause</i>	1592
Allelic Loss of Chromosome 17P in Urothelial Cancer: Strong Association With Invasive Phenotype. <i>T. Habuchi, O. Ogawa, Y. Kakehi, K. Ogura, M. Koshiba, T. Sugiyama and O. Yoshida</i>	1595
Establishment and Characterization of Human Primary Prostatic Adenocarcinoma Cell Line (ND-1). <i>P. Narayan and R. Dahiya</i>	1600
In Vitro Studies on Effect of Cofactors on 5 α -Reductase and 3 α - and 3 β -Hydroxysteroid Reductase Activities in Hyperplastic Human Prostate. <i>M. E. Lombardo, S. I. Hakky, M. K. Hall and P. B. Hudson</i>	1605
Urinary Bladder Function in Tight-Skin Mouse. <i>P. A. Longhurst, B. Eika, R. E. Leggett and R. M. Levin</i>	1611
Comparison of Urinary Bladder Function in 6 and 24 Month Male and Female Rats. <i>P. A. Longhurst, B. Eika, R. E. Leggett and R. M. Levin</i>	1615

UROLOGICAL SURVEY

Principles of Oncology and Immunology, and Tumors of Bladder, Penis and Urethra	1622
Male Infertility	1626
Sexual Function and Dysfunction	1628
Renal Calculi	1630
Renal Tumors, Retroperitoneum, Ureter, and Urinary Diversion and Reconstruction	1633
Book Reviews	1635

News and Announcements	1637
-------------------------------------	------

PROPRIETARY NAMES

Many of the words appearing in the JOURNAL OF UROLOGY are proprietary names even though no reference to this fact is made in the text. The appearance of any name without designation as proprietary is, therefore, not to be regarded as a representation by the editorial committee or publisher that it is not the subject of proprietary rights.

GUIDELINES FOR SUPPLEMENTS

The Editors of the Journal will consider requests for and solicit sponsors of Supplements to The Journal of Urology. For those interested the following are the proposed steps for publication of a Supplement.

1) Proposal formulated by sponsors of the Supplement or solicited by the Journal Editorial Staff that would include an indication of the major topics with a limited outline of subtopics, the nature of the articles to be included (review, original papers with or without discussion), identification of a sponsoring group or individual, identification of the type of internal quality control group available for the Journal Editors to work with and an indication of the financial support available.

2) Response by the Editorial Staff with identification of a specific individual to work with the Editorial Committee of the sponsors.

3) Agree to a deadline for submission of the papers, number of papers and so forth.

4) Formulation of and agreement on procedure for initial screening and editorial evaluation of manuscripts and discussions with active participation by the sponsoring group.

5) Submission to the Editorial Staff of the Journal for their evaluation.

6) Interaction between Journal and sponsoring editorial group. Final decision is retained by Journal Editorial Staff.

7) Redaction, page proofing and so forth by Editorial Staff. Articles in supplements would be indexed in the Journal.

8) Publication.

DISCLAIMER

The statements and opinions contained in the articles of JOURNAL OF UROLOGY are solely those of the individual authors and contributors and not of the American Urological Association, Inc. or Williams & Wilkins. The appearance of the advertisements in the Journal is not a warranty, endorsement or approval of the products or services advertised or of their effectiveness, quality or safety. The American Urological Association, Inc., and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

PRELIMINARY RESULTS WITH THE NITRIC OXIDE DONOR LINSIDOMINE CHLORHYDRATE IN THE TREATMENT OF HUMAN ERECTILE DYSFUNCTION

CHRISTIAN G. STIEF, FREDRIK HOLMQUIST, MOHAMAD DJAMILIAN, HELMUT KRAH, KARL-
ERIK ANDERSSON AND UDO JONAS

From the Department of Urology, Medical School, Hannover, Germany and Department of Clinical Pharmacology, University Hospital, Lund, Sweden

ABSTRACT

Recent experimental studies showed an important role of endothelium derived relaxing factor for cavernous smooth muscle relaxation. Since nitric oxide seems to account for the biological actions of endothelium derived relaxing factor, a study was done to examine a possible role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the treatment of erectile dysfunction.

To determine a therapeutically useful dose 0.1, 0.2, 0.5 and 1 mg. SIN-1 were injected intracavernously in patients with erectile dysfunction. Each dose was given to 2 patients. Then, 63 patients received 1 mg. SIN-1, including 7 who had prolonged erections to minimal doses of papaverine plus phentolamine and 4 who did not respond with a full erection to other pharmacological agents. Intracavernous injection of SIN-1 induced a dose-dependent erectile response by increasing the arterial inflow and relaxing cavernous smooth muscles. Of the patients 29 had a full, 21 an almost full and 13 a moderate erection to 1 mg. SIN-1. There were no systemic or local side effects. In the patients with prolonged erections to papaverine plus phentolamine the mean duration of a full erectile response to SIN-1 was 57 minutes. Compared to the responses to a papaverine (15 mg./ml.) and phentolamine (0.5 mg./ml.) mixture, the erection induced by SIN-1 was superior in 10, comparable in 47 and inferior in 6 patients.

Our data suggest a possible role for SIN-1 in the treatment of erectile dysfunction. Possible advantages may be that erection is induced by a mechanism similar to that occurring physiologically, a decreased risk of inducing prolonged erections and low therapy costs.

KEY WORDS: penile erection, impotence, nitric oxide

Cavernous smooth muscles have a crucial role in penile erection. Relaxation of the arterial and sinusoidal cavernous smooth muscles induces an erection by decreasing peripheral resistance, entrapping blood within the sinusoids and restricting cavernous outflow.¹ In vascular smooth muscle endothelium derived relaxing factor is an important physiological mechanism for relaxation.² The current view is that nitric oxide or a nitric oxide-containing compound, synthesized from L-arginine, accounts for the biological actions of endothelium derived relaxing factor.³ Recent *in vitro* studies on rabbit and human penile tissues have shown that nitric oxide or a nitric oxide-containing compound, probably released from nerves, has a role in the regulation of cavernous smooth muscle tone.⁴⁻⁷ *In vivo* studies in rabbits further support a role for the L-arginine/nitric oxide pathway in penile erection.⁸

These experimental data suggest that in the treatment of erectile dysfunction use of the L-arginine/nitric oxide pathway may be an interesting approach, since it would resemble the physiological sequence of events in erection. Linsidomine chlorhydrate (SIN-1) is the active metabolite of the antianginal drug molsidomine⁹ (N-ethoxycarbonyl-3-morpholino-sydnominine) and it is believed to liberate nitric oxide nonenzymatically (nitric oxide donor). Preliminary results showed that SIN-1 produces an erection in patients with erectile dysfunction.¹⁰ We examined the effects of intracavernous application of SIN-1 in 63 men with erectile dysfunction, and evaluated its possible therapeutic potential in the treatment of erectile dysfunction.

PATIENTS AND METHODS

SIN-1 was injected intracavernously in 63 patients from our impotence clinic. Before entering the study the patients underwent a comprehensive evaluation regarding the etiology of the erectile dysfunction, including case history, physical examination, sexual case history (by a psychiatrist), blood laboratory studies, pharmaco-Doppler ultrasound, single potential analysis of cavernous electrical activity evaluation¹¹ and pharmacological testing.¹² When indicated by case history or the aforementioned examinations,¹² pharmaco-angiography or cavernosometry was done. In case the standardized medication of 15 mg./ml. papaverine and 0.5 mg./ml. phentolamine, with a maximal dose of 3 ml., did not induce a full erection (at least 3 intracavernous injections were done), prostaglandin E1 (maximal dose 40 µg.) was applied. In case of incomplete erection to prostaglandin E1 a combination of 10 µg. prostaglandin E1 and 5 µg. calcitonin gene-related peptide¹³ was tried. All injections were done with the patient in the supine position. Only 1 dose a day was injected. To enhance reproducibility the patients were advised to restrain from psychogenic or reflexogenic stimulation. The erectile response was evaluated by a urologist 10, 20 and 30 minutes after the injection.

After the diagnostic evaluation all patients were injected with SIN-1 intracavernously. Before the injection the patients were extensively informed about the study and about possible side effects (prolonged erections, systemic side effects, such as decreased blood pressure with unconsciousness, cavernous fibrosis and infection). After the explanation written consent was obtained from each patient. The study was approved by the Ethics Committee of the University of Hannover (approval No. 532).

SIN-1 is officially approved for treatment of coronary spasms

Accepted for publication March 13, 1992.
Supported by grants Sti 96/2-2 from the Deutsche Forschungsgemeinschaft and the Swedish Medical Research Council (No. 6837).




FIG. 1. Intracavernous injection of 0.5 mg. SIN-1 in 51-year-old patient with venogenic and arteriogenic erectile dysfunction induced significant increase in penile arterial blood flow velocity during 140 minutes (continuous wave Doppler ultrasound, 8 MHz. probe). 1, Doppler signals before SIN-1. 2, 3 minutes after intracavernous injection of 0.5 mg. SIN-1 (E1). 3, 10 minutes after SIN-1 (E2). 4, 35 minutes after SIN-1 (E4).




FIG. 2. Recording of cavernous electric activity (frequency range 0.5 to 500 Hz.) with 2 needle electrodes, 1 in each corpus, in 39-year-old patient with erectile dysfunction, negative organic findings and high probability of psychogenic etiology. *a*, upper recording shows normal electric activity in flaccid state (recorded during 40 minutes), synchronous in both cavernous bodies with upper tracing in right and lower in left cavernous body. *b*, 20 seconds after intracavernous injection of 1 mg. SIN-1. Lower recording shows dramatically reduced cavernous electric activity in both cavernous bodies, with only short lasting potentials of low amplitude (arrows) in left corpus. This reduced cavernous electric activity lasted more than 60 minutes (end of registration).

and for angiography of the coronary arteries. The dosage recommended by the manufacturer is 0.4 to 1 mg. Therefore, we applied 0.1 mg. in 2 patients, 0.2 mg. in 2 and 0.5 mg. in 2. Since a main purpose of this study was to evaluate a therapeutically useful dose, considering effect versus possible side effects, such as pain, prolonged erections and systemic reactions, all patients (including the aforementioned 6) received 1 mg. Nine patients were also given 2 mg. SIN-1, since 1 mg. induced only an insufficient (less than category E5) erectile response. In 6 of these 9 patients SIN-1 was considered the last therapeutic alternative regarding available drugs for autoinjection therapy. Since a possible therapeutic use of SIN-1 was to be

evaluated, patients receiving 2 mg. SIN-1 were advised to use additional reflexogenic and/or psychogenic stimulation to improve the erectile response. The first 2 of these 9 patients were medical doctors. Before the injection all patients receiving 2 mg. SIN-1 were informed about the unusually high dose with possible severe systemic side effects (hypotension and hypovolemic shock). The local response to SIN-1 was measured by inspection and palpation by a urologist; the erectile response was classified into 6 categories: E0—no response, E1—minimum tumescence, E2—medium tumescence, E3—full tumescence without rigidity, E4—full tumescence with medium rigidity and E5—full erection. Bidirectional Doppler sonography of the 4 penile arteries was done in the first 6 injections, 2 patients each receiving 0.1, 0.2 and 0.5 mg. SIN-1. Single potential analysis of cavernous electrical activity was done in 2 patients receiving 1 mg. SIN-1. Pulse and blood pressure were closely monitored in the first 8 patients. During the entire procedure the patient was in the supine position.

RESULTS

At the dosages used intracavernous application of SIN-1 induced an erectile response in all patients. The erectile response, measured by tumescence and rigidity, as well as by arterial flow velocity, was dose-dependent. Intracavernous injection of 0.1 mg. SIN-1 (2 patients) induced a medium tumescence without rigidity (E2) after a mean of 15 minutes and lasting for 45 minutes. By Doppler sonography a significant increase in cavernous arterial flow was observed for a mean of 85 minutes. Intracavernous injection of 0.2 mg. SIN-1 (2 patients) induced an almost full erection (E4 to E5) for 40 minutes and a significant increase in arterial flow was observed for 135 minutes. Intracavernous injection of 0.5 mg. SIN-1 (2 patients) induced a full erection (E5) in 1 patient for 40 minutes and full tumescence with medium rigidity (E4) in 1, and an increase in arterial inflow was observed for a mean of 150 minutes (fig. 1). Recording of cavernous electrical activity showed disappearance of the potentials about 20 seconds after the intracavernous injection of 1 mg. SIN-1 in both patients (fig. 2). Intracavernous injection of 1 mg. SIN-1 was done in 63 patients and induced a full erection (E5) in 29, full tumescence with medium rigidity (E4) in 21 and full tumescence (E3) in 13.

In 9 of the patients with an incomplete erectile response (E3) to 1 mg. SIN-1 pharmacocavernosometry showed venous leakage. These patients were injected with 2 mg. SIN-1. Among the 9 patients who received intracavernous injection of 2 mg. SIN-1 an almost full erection (E4 to E5) was observed in 4, while 5 achieved an erectile response (E4) comparable to that obtained with 1 mg. SIN-1. All 4 patients with an almost full erection after 2 mg. SIN-1 achieved a full erection (E5) with additional stimulation. Comparing the maximal erectile response to SIN-1 to that of the combination of papaverine and phentolamine, SIN-1 was superior in 10 of the 63 patients, comparable in 47 and inferior in 6.

In 2 of 4 patients with insufficient erectile response to maximal doses of papaverine (45 mg.) plus phentolamine (1.5 mg.), prostaglandin E1 (40 μ g.) and the combination of prostaglandin E1 (10 μ g.) plus calcitonin gene-related peptide (5 μ g.)¹⁴ intracavernous injection of 2 mg. SIN-1 induced an almost full erection (E4 to E5), which became a full erection with additional stimulation. Both patients are currently on SIN-1 autoinjection therapy.

A total of 4 patients did not respond to maximal doses of papaverine plus phentolamine or prostaglandin E1 with a full erection. The combination of 10 μ g. prostaglandin E1 plus 5 μ g. calcitonin gene-related peptide induced a full erection (E5) for 60 minutes. In these patients intracavernous injection of 1 mg. SIN-1 induced only an incomplete erectile response (E3 or E4). In 2 other patients responding better to the papaverine-

phentolamine combination the diagnostic evaluation was highly suspicious for pure psychogenic impotence.

A total of 7 patients showed a pure neurogenic etiology for the erectile dysfunction on diagnostic evaluation. A dosage of 1 mg. SIN-1 was injected into 6 patients with long lasting full erections to relatively small doses of the combination of papaverine and phentolamine. With a mean dose of 0.33 ml. (5 mg. papaverine and 0.16 mg. phentolamine) 4 of the 6 men had a mean full erectile duration of 230 minutes; 2 of them presented with 2 episodes of prolonged erection. Another patient was transferred to us because multiple prolonged erections developed of about 40 hours to doses of 20 mg. papaverine. In these 7 patients intracavernous injection of 1 mg. SIN-1 induced a full erection lasting for 40 to 90 minutes (mean 57 minutes).

In all but 1 patient the injection of SIN-1 induced no objective or subjective systemic side effects. One patient reported sweating after intracavernous injection of 2 mg. SIN-1. No patient reported pain or burning during or after the intracavernous injection of SIN-1. Of the patients who were on papaverine and phentolamine autoinjections 4 noticed subjectively that intracavernous application of SIN-1 was much more comfortable than injection of the papaverine-phentolamine mixture.

DISCUSSION

Our study shows that the intracavernous injection of SIN-1 induces a dose-dependent erectile response. By Doppler sonography we could demonstrate that this erectile response is accompanied by a dramatic increase in cavernous arterial blood flow. In vitro studies showed cavernous smooth muscle relaxation to SIN-1.⁷ These findings are in agreement with our recordings of cavernous electrical activity before and after intracavernous injection of SIN-1. We found an almost complete disappearance of cavernous electrical activity after SIN-1, which shows that the erectile response to intracavernous SIN-1 is due to cavernous smooth muscle relaxation.¹¹

Comparing the maximal erectile responses, the erection induced by SIN-1 was superior to that produced by the combination of papaverine and phentolamine in 10 of 63 patients, comparable in 47 patients and inferior in 6. The mechanisms behind the effects of the combination are complex, and probably not only include the phosphodiesterase inhibiting effects of papaverine and the α -adrenoreceptor blocking effect of phentolamine but additional actions. SIN-1 is believed to liberate nitric oxide nonenzymatically, which, in turn, stimulates guanylate cyclase leading to an increase in the intracellular concentration of cyclic guanosine 3', 5' monophosphate. SIN-1 also hyperpolarizes the cell membrane by influencing the sodium-potassium pump,¹⁴ thus rendering the smooth muscle cell less responsive to adrenergically mediated contraction. The actions of the papaverine-phentolamine combination and of SIN-1 are not dependent on an intact endothelium, which should make both alternatives effective also in cases when the erectile dysfunction may be due to endothelial malfunction, such as in diabetes mellitus or hypercholesterolemia.¹⁵⁻¹⁷ Our series suggests SIN-1 to be comparable or even superior to the combination of papaverine and phentolamine. However, controlled comparative studies are needed to strengthen these assumptions. Furthermore, the reasons for possible differences in efficacy remain to be established.

In 4 of 63 patients who received SIN-1 neither 45 mg. papaverine plus 1.5 mg. phentolamine, 40 μ g. prostaglandin E1 nor 10 μ g. prostaglandin E1 plus 5 μ g. calcitonin gene-related peptide induced an erectile response allowing intercourse (even with additional stimulation). In 2 of these 4 patients intracavernous injection of SIN-1 combined with stimulation induced a full erection, thus enabling the patients to have intercourse without the insertion of a penile prosthesis or application of a vacuum device. We have no explanation for the apparent better efficacy of SIN-1 in these patients. It is known that the number

of prostaglandin E1 receptors is reduced in several diseases, such as diabetes mellitus,¹⁸ and that this may contribute to a lesser effect. In such cases SIN-1 may be an effective alternative.

A 1 mg. dose of SIN-1 was injected into 6 patients with long lasting full erections to small doses of the papaverine-phentolamine combination. History revealed a spinal cord injury (complete below T11) in 1 patient and a vertebral nucleus prolapse (L4/L5) in 1. In 4 patients abnormal single potential analysis of cavernous electrical activity findings was obtained, with the other examinations being normal. With a mean dose of 0.33 ml. (5 mg. papaverine and 0.16 mg. phentolamine) 4 of 6 men had a mean duration of a full erection of 230 minutes (2 of them presented with episodes of prolonged erections). One patient was transferred to us because of multiple prolonged erections about 40 hours in duration with doses of 20 mg. papaverine. The diagnostic constellation in these 7 patients is highly suggestive of pure neurogenic impotence. Although these patients are usually overreactive to intracavernous pharmacotherapy, intracavernous injection of 1 mg. SIN-1 induced a full erection lasting 40 to 90 minutes (mean 57 minutes). This finding may be explained by the local pharmacokinetics of SIN-1 and the rapid decomposition of nitric oxide within the cavernous tissue, which should prevent the occurrence of prolonged erections.

Most patients on autoinjection therapy with a papaverine-phentolamine mixture report a slight burning sensation at the injection site during injection of the drug mixture. No patient who received SIN-1 intracavernously reported any pain or burning sensation during or after the injection. This observation may further indicate the fact that SIN-1 is well tolerated by the cavernous tissue.

In animal studies¹⁹ as well as at followup of patients on autoinjection therapy,²⁰ chronic intracavernous injection of papaverine has been shown to result in significant cavernous fibrosis. Chronic intracavernous injection of prostaglandin E1 seems to have less fibrotic potential on cavernous tissue, as shown in animal¹⁹ and human studies.²⁰ Since SIN-1 is delivered as lyophilized powder to be dissolved in physiological (0.9%) saline solution, it should also have minor fibrotic effects on the cavernous tissue. Nevertheless, chronic animal studies are urgently needed to elucidate this important issue. Since therapy costs are of increasing importance in all countries, the cost of SIN-1 therapy is of interest (the prices indicated are those for Germany and France, respectively). The cost of 1 ampule of SIN-1 (1 mg. delivered lyophilized with 1 ampule 0.9% saline solution) equals approximately the cost of an ampule of papaverine (30 mg. in solution) and is approximately one-fifth of the cost of prostaglandin E1 (20 μ g. lyophilized, delivered without solution for dissolution). Thus, SIN-1 seems to be an affordable alternative in the treatment of erectile dysfunction.

In conclusion, our preliminary results suggest that SIN-1 is an attractive option in the autoinjection therapy for erectile dysfunction. The absence of prolonged erections, the high effectiveness to induce a sufficient erectile response and the low cost indicate the potential of SIN-1 to become a standard drug for intracavernous injections. Before widespread use can be advocated, long-term animal studies must examine the local effect of this agent on the cavernous tissue.

REFERENCES

1. Lue, T. F. and Tanagho, E. A.: Physiology of erection and pharmacological management of impotence. *J. Urol.*, **137**: 829, 1987.
2. Furchgott, R. F. and Zawadzki, J. V.: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*, **288**: 373, 1980.
3. Moncada, S., Palmer, R. M. J. and Higgs, E. A.: Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol. Rev.*, **43**: 109, 1991.

4. Ignarro, L. J., Bush, P. A., Buga, G. M., Wood, K. S., Fukuto, J. M. and Rajfer, J.: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. *Biochem. Biophys. Res. Comm.*, **170**: 843, 1990.
5. Holmquist, F., Hedlund, H. and Andersson, K.-E.: L-N^G-nitro arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. *Acta Physiol. Scand.*, **141**: 441, 1991.
6. Kim, N., Azadzi, K. M., Goldstein, I. and de Tejada, S. I.: A nitric oxide-like factor mediates nonadrenergic noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. *J. Clin. Invest.*, **88**: 112, 1991.
7. Holmquist, F., Hedlund, H. and Andersson, K. E.: Characterisation of inhibitory neurotransmission in the isolated corpus cavernosum from rabbit and man. *J. Physiol.*, in press.
8. Holmquist, F., Stief, C. G., Jonas, U. and Andersson, K.-E.: Effects of the nitric oxide synthase inhibitor N^G-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. *Acta Physiol. Scand.*, **143**: 299, 1991.
9. Reden, J.: Molsidomine. *Blood Vessels*, **27**: 282, 1990.
10. Stief, C. G., Holmquist, F., Allhoff, E. P., Andersson, K. E. and Jonas, U.: Preliminary report on the effect of the nitric oxide donor SIN-1 on human cavernous tissue in vivo. *World J. Urol.*, **9**: 237, 1991.
11. Stief, C. G., Djamilian, M., Schaebsdau, F., Truss, M. C., Schlick, R., Abicht, J. H., Allhoff, E. P. and Jonas, U.: Single potential analysis of cavernous electric activity—a possible diagnosis of autonomic impotence. *World J. Urol.*, **8**: 75, 1990.
12. Stief, C. G., Bähren, W., Gall, H. and Scherb, W.: Functional evaluation of penile hemodynamics. *J. Urol.*, **139**: 734, 1988.
13. Stief, C. G., Wetterauer, U., Schaebsdau, F. H. and Jonas, U.: Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutical application in impotent patients. *J. Urol.*, **146**: 1010, 1991.
14. Vanhoutte, P. M.: Vascular physiology: the end of the quest? *Nature*, **327**: 459, 1987.
15. Saenz de Tejada, I., Goldstein, I., Azadzi, K., Krane, R. J. and Cohen, R. A.: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. *New Engl. J. Med.*, **320**: 1025, 1989.
16. Azadzi, K. M. and Saenz de Tejada, I.: Inhibition of endothelium-dependent relaxation by hypercholesterolemia in rabbit corpus cavernosum smooth muscle. *J. Urol.*, part 2, **145**: 230A, abstract 72, 1991.
17. Mersdorf, A., Goldsmith, P. C., Diederichs, W., Padula, C. A., Lue, T. F., Fishman, I. J. and Tanagho, E. A.: Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. *J. Urol.*, **145**: 749, 1991.
18. Aboseif, S., Riemer, K., Stackl, W., Lue, T. and Tanagho, E.: Quantification of prostaglandin E1 receptors in the cavernous tissue of humans, primates and canines. *J. Urol.*, part 2, **145**: 230A, abstract 70, 1991.
19. Aboseif, S. R., Breza, J., Diederichs, W., Bosch, R., Benard, F., Stief, C. G., Lue, T. F. and Tanagho, E. A.: Effect of chronic intracavernous injection of papaverine and prostaglandin E1 on erectile tissue in monkeys. *J. Urol.*, part 2, **139**: 257A, abstract 377, 1988.
20. Jünemann, K.-P. and Alken, P.: Pharmacotherapy of erectile dysfunction: a review. *Int. J. Impotence Res.*, **1**: 71, 1989.